New Publication: Reaksi Drug Safety News - Issue 4/2017 Print User Rating: 1 / 5 Please Rate Vote 1 Vote 2 Vote 3 Vote 4 Vote 5 REAKSI Drug Safety News, Issue 4/2017, Vol. 36 Hyoscine Butylbromide Injection: Risk of Serious Adverse Effects in Patients with Underlying Cardiac Disease Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) DOWNLOAD PDF